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A chemical derivative of the thiopeptide GE2270A, designated NAI003, was found to possess a substantially reduced antibacte-
rial spectrum in comparison to the parent compound, being active against just a few Gram-positive bacteria. In particular,
NAI003 retained lowMICs against all tested isolates of Propionibacterium acnes and, to a lesser extent, against Enterococcus
faecalis. Furthermore, NAI003 showed a time- and dose-dependent killing of both a clindamycin-resistant and a clindamycin-
sensitive P. acnes isolate. Gel shift experiments indicated that, like the parent compound, NAI003 retained the ability to bind to
elongation factors Tu (EF-Tus) derived from Escherichia coli, E. faecalis, or P. acnes, albeit with reduced efficiency. In contrast,
EF-Tus derived from the NAI003-insensitive Staphylococcus aureus or Streptococcus pyogenes did not bind this compound.
These results were confirmed by in vitro studies using a hybrid translation system, which indicated that NAI003 can inhibit most
efficiently protein synthesis driven by the P. acnes EF-Tu. P. acnesmutants resistant to NAI003 were isolated by direct plating.
With one exception, all analyzed strains carried mutations in the tuf gene, encoding EF-Tu. Because of its selective effect on P.
acnes in comparison to resident skin flora, NAI003 represents a promising candidate for the topical treatment of acne, which has
already completed a phase 1 clinical study.
Acne vulgaris, a complex disease of the pilosebaceous units ofthe face and upper trunk, is themost common skin condition
seen by physicians. Although it affects almost 100%of adolescents
to various degrees and generally wanes as adolescence ends, the
disease may persist into adulthood, and it has been estimated that
more than 17 million people in the United States are affected by
acne (1, 2). At least four factors contribute to the development of
acne: increased sebum production by the sebaceous glands, follic-
ular hyperkeratinization, colonization of the sebaceous follicles
with Propionibacterium acnes, and inflammation (3, 4).
Inflammatory acne is the result of the host response to P. acnes,
a pleomorphic, anaerobic rod belonging to the phylumActinobac-
teria. P. acnes, a component of the normal skin flora, is a usually
harmless commensal largely incapable of tissue invasion or seri-
ous infection. The organism catabolizes sebaceous triglycerides,
using the glycerol moiety as a carbon source without catabolizing
the fatty acids. While this species has been advocated to play a
fundamental role in the etiogenesis of acne (5, 6), a significant
controversy remains as to how important a role P. acnes plays (4,
7). Recent metagenomic studies have confirmed it to be themajor
inhabitant of pilosebaceous units (8). Nonetheless, P. acnes is a
normal skin commensal not necessarily associated with acne, al-
though a correlation between disease and P. acnes phylotypes has
been proposed (8). It is also worth pointing out that Staphylococ-
cus epidermidis can produce catabolites that inhibit P. acnes
growth (9), highlighting the importance of an appropriate balance
of the microflora for a healthy skin. On the basis of the above
considerations, a reduction in the population of P. acnes without
affecting other commensal flora may constitute a plausible ap-
proach to an effective therapy of acne. However, no antibacterial
agent possessing such an antibacterial spectrum has been de-
scribed so far.
The thiopeptide GE2270A 1, produced by the actinomycete
Planobispora rosea, is extremely active against numerous Gram-
positive pathogens, including methicillin-resistant strains of
Staphylococcus aureus and vancomycin-resistant Enterococcus spp.
(10). It has been demonstrated that GE2270A binds to domain II
of elongation factor Tu (EF-Tu), making contacts with residues
215 to 230, 256 to 264, and 273 to 277 (11). These interactions alter
the conformation of EF-Tu, so as to increase its electrophoretic
mobility (12) and to inhibit EF-Tu–GTP–aminoacyl-tRNA
(aa-tRNA) ternary complex formation. As a result, GE2270A in-
terferes selectively with the functioning of the elongation factor in
protein synthesis.
During a program aimed at generating analogs of GE2270A by
semisynthesis, we observed that one of the derivatives, designated
NAI003, showed a surprisingly restricted antibacterial spectrum,
mostly limited to P. acnes. Here, we report the antibacterial prop-
erties of this compound, investigate the molecular basis for its
reduced activity against other Gram-positive bacteria, and pro-
vide evidence that NAI003 targets EF-Tu in P. acnes.
MATERIALS AND METHODS
Chemistry. GE2270A (5 g, 3.87 mmol), prepared as described previously
(10), was dissolved in dioxane-water-formic acid (10:1:1) and left over-
night at 80°C under stirring. After cooling, the solvent was evaporated and
concentrated to dryness, and the resulting residue was incubated for 1 h at
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room temperature in 0.5 M sodium carbonate. The reaction mixture was
then diluted with cold water and brought to pH 6.5 with HCl. The thio-
peptides were extracted from the aqueous phase with ethyl acetate and
then precipitated from the concentrated organic phase by adding petro-
leum ether. The resulting solid (1.3 g, 1 mmol) was dissolved in dimeth-
ylformamide (DMF) (10 ml), and 4-amino-N-benzylpiperidine (1.2
mmol), triethanolamine (TEA) (1.4 mmol), and diphenyl phosphorazi-
date (1.2mmol)were added at 0°C. The temperaturewas allowed to rise to
room temperature, and stirring was continued for about 4 h. The reaction
mixture was acidified to pH 3with 1NHCl and then diluted with water to
complete precipitation of the product. The wet solid was dried in air and
then purified by flash chromatography (silica gel 60, 230 to 400 mesh;
ASTM; Merck) with elution with 3 to 5% methanol in chloroform. Frac-
tions containing NAI003 were pooled and evaporated to dryness as a
white solid. The data are as follows: 1H nuclear magnetic resonance
(NMR), dimethyl sulfoxide (DMSO)-d6 0.86 (d, 3H); 0.90 (d, 3H); 1.91 to
1.70 (n, 2H); 2.26 to 2.05 (m, 2H); 2.60 (s, 3H); 2.91 to 2.69 (m, 4H); 3.40
(s, 3H); 3.51 (br s, 2H); 3.95 to 3.75 (m, 2H); 4.30 (dd, 1H); 4.99 (s, 2H);
7.41 to 7.18 (m, 2H); 8.28 (s, 1H); 8.45 (s, 1H); 8.66 (s, 1H).
Bacterial strains andmedia.Bacterial strains were frompublic collec-
tions (ATCC) or from the Naicons collection of pathogenic strains (des-
ignated by “L” or “ND” prefixes). In particular, theP. acnes strains with an
“L” or “ND” prefix were independent clinical isolates collected before
2003 and in 2011, respectively. Brucella broth (BB) and brucella agar
(BA), Middlebrook 7H9 broth (7H9B), Mueller-Hinton broth (MHB),
Todd-Hewitt broth (THB), and Wilkins-Chalgren agar (WCA) were
from Difco Laboratories (Detroit, MI, USA). Cation-adjusted MHB
(CAMHB), prepared by adding 20 mg/ml CaCl2 and 10 mg/ml MgCl2 to
MHB,was used for all aerobic bacteria except for streptococci, whichwere
grown in THB; Corynebacterium sp., which was grown in CAMHB with
5% lysed horse blood; andMycobacterium smegmatis, which was grown in
7H9B supplemented with 0.5 g/liter Tween 80 and 10% oleic acid-albu-
min-dextrose-catalase (OADC) enrichment (BD,MD,USA). P. acneswas
grown in BB or BA supplemented with 5% lysed horse blood, 5 g/ml
hemin, and 1 g/ml vitamin K1 (supplemented BB). All liquid media
contained 0.02% bovine serum albumin, unless otherwise noted. All cul-
tures were grown at 37°C.
Determination of MICs. MICs were determined by the broth mi-
crodilution methodology (13, 14); bacteria were inoculated at 5  105
CFU/ml. Assays were performed in sterile 96-well microtiter plates with
round-bottomed wells. Plates were read after 20 to 24 h (aerobic bacteria)
or 72 h (Mycobacterium smegmatis; P. acnes, anaerobic atmosphere).
GE2270A and its derivatives were dissolved in dimethyl sulfoxide. Clin-
damycin and erythromycin (Sigma-Aldrich) were dissolved in water and
in 95% ethanol, respectively. Appropriate dilutions were made with the
required culture medium immediately before testing.
Time-kill assays. P. acnes colonies from 72-h BA plates were resus-
pended in BB at approximately 1 105 to 2 105 CFU/ml and incubated
for 24 h in supplemented BB. Then, 0.5 ml of the culture was added to
fresh 5 ml supplemented BB in glass vials with plastic caps containing the
desired concentration of antibiotic. For this experiment, a series of anti-
biotic solutions were made at 100 the desired final concentration in
eitherDMSO(forNAI003) orwater (for clindamycin). In all experiments,
an extra vial, supplemented with just 50 l DMSO, was used as a growth
control. Cultures were incubated at 37°C, and anaerobic conditions were
achievedwith 1:25 (vol/vol)Oxyrase (Oxyrase Inc.,Mansfield,OH,USA).
At different time points, 0.2-ml aliquots were withdrawn and serially di-
luted 1:10with 0.9%NaCl, and 25l of each dilutionwas spread onto two
to four BA plates. Colonies were counted after 48 to 72 h at 37°C under an
anaerobic atmosphere and average values used in time-kill curves (varia-
tions in colony numbers were usually within30% of average counts).
Resistance analysis.The occurrence of spontaneous resistantmutants
of P. acnes ATCC 6922 was determined by plating 0.1 ml of a stationary-
phase culture onWCA containing NAI003 or GE2270A at 1 or 10 g/ml.
Plates were incubated in an anaerobic atmosphere, with colonies scored
after 5 and 12 days. Colonies emerging on the plates were cultured in BB,
centrifuged, and stored at 80°C in nutrient broth supplemented with
20% glycerol for MIC determination and analysis of the tuf genes, encod-
ing EF-Tu. From selected strains, a cell lysate wasmade by heating at 95°C
for 5 min and used for PCR amplifying the entire tuf gene with primers
5=-GTGGCAAAGGCCAAGTTCG-3= and 5=-TCACTTGATGATCTTGG
TGACTC-3=. PCR products were directly sequenced (Primm Srl, Mi-
lan, Italy). The sequenced segment from the parental strain ATCC
6922 was found to be identical to the tuf gene from P. acnesKPA171202
(15) (GenBank NC_006085.1).
Biochemical methods. Buffers used were the following: buffer A, 25
mM Tris-HCl (pH 7.1), 5% glycerol, 700 mM NaCl, 6 mM -mercapto-
ethanol, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM benz-
amidine; buffer B, 25mMTris-HCl (pH 7.1), 300mMNaCl, 5% glycerol,
20mM imidazole, 6mM-mercaptoethanol, 0.1mMPMSF, and 0.1mM
benzamidine; buffer C, 25 mM Tris-HCl (pH 7.1), 300 mM NaCl, 5%
glycerol, 300 mM imidazole, 6 mM -mercaptoethanol, 0.1 mM PMSF,
0.1 mM benzamidine; buffer D, 20 mM Tris-HCl (pH 7.1), 100 mM
NH4Cl, 5% glycerol, 6 mM -mercaptoethanol, 0.1 mM EDTA; buffer E,
10 mM Tris-HCl (pH 7.7), 10 mMmagnesium acetate, 60 mM NH4Cl.
Cloning, overexpression, and purification of EF-Tus. The strategy
used to clone the tuf genes from genomic DNA of S. aureus (ATCC
25923), Enterococcus faecalis (ATCC 29922), Streptococcus pyogenes
(ATCC 700294), and P. acnes (ATCC 6919) was essentially as reported by
Zeng (16). Briefly, four different phosphorylated primers (Table 1) carry-
ing NcoI and BamHI restriction sites were used in two separate DNA
amplification reactions. Equal volumes of the two PCR mixtures were
combined and subjected to a 5-min denaturation at 95°C and a 15-min
renaturation at room temperature. Of the resulting final products, 25%
are expected to carryNcoI and BamHI cohesive ends, which can be ligated
with the appropriately restricted expression vector pETM11. The ligation
products were then transformed into the Escherichia coli BL21 strain.
E. coli BL21(DE3)pLysS cells harboring the pETM11 derivatives were
grown in LB medium at 37°C up to an optical density at 600 nm (OD600)
of 0.7, when 1 mM isopropyl--D-1-thiogalactopyranoside was added.
After 4 h at 37°C, the cells were harvested by centrifugation at 5,000 rpm
for 10 min at 4°C and the pellet, resuspended in buffer A, was stored at
80°C. After thawing, the cells were lysed by sonication, and the resulting
cell extract was cleared by centrifugation at 13,000 rpm for 45 min at 4°C.
The cell extract was subsequently loaded on a 5-ml nickel-nitrilotriacetic
TABLE 1 Oligonucleotide primers used for sticky-end PCR
tufA gene source Sequence (5=-3=)a
S. aureus F: CATGGCAAAAGAAAAATTCGATCGTTC
R: CTTATTTAATGATTTCAGTAACAACGC
F: GCAAAAGAAAAATTCGATCGTTCTAAAG
R: GATCCTTATTTAATGATTTCAGTAACAACG
E. faecalis F: CATGGCAAAAGAAAAATTTGACCGTTC
R: CTTATTTAATGATTTCAGTAACAACGC
F: GCAAAAGAAAAATTTGACCGTTCTAAATC
R: GATCCTTATTTAATGATTTCAGTAACAACG
S. pyogenes F: CATGGCAAAAGAAAAATACGATCGTAG
R: GATCCTTAAGCTTCGTTTCTGAAACG
F: GCAAAAGAAAAATACGATCGTAGTAAAC
R: CTTAAGCTTCGATTTCTGAAACGATACC
P. acnes F: CATGGCAAAGGCCAAGTTCGAGCGG
R: GATCCTCACTTGATGATCTTGGTGACTCG
F: GCAAAGGCCAAGTTCGAGCGGACC
R: CTCACTTGATGATCTTGGTGACTCGACC
a F, forward; R, reverse. The methodology employed (16) requires two forward and two
reverse primers for each amplification.
P. acnes Selective Thiopeptide
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acid (Ni-NTA) chromatographic column equilibrated in buffer A. The
columnwas initially washed with 10 bed volumes of buffer A, followed by
an additional washwith 5 bed volumes of buffer B. EF-Tuwas eluted from
the column with buffer C. Fractions containing EF-Tu were dialyzed to
reduce salt concentration against buffer C containing 100 mM NaCl
(without imidazole) and digested by tobacco etch virus (TEV) protease
(enzyme/substrate ratio, 1:40) overnight at 20°C, with 20% extra TEV
protease added for an additional 3 to 4 h. The reaction mixture was again
loaded on the Ni-NTA resin, and the cleaved protein, without the His tag,
was recovered in the flowthrough of the column. EF-Tuwas concentrated
by centrifugation at 4,000 rpm for 60 min at 4°C in Amicon Ultra-3 cen-
trifugal filter devices, and after dialysis at 4°C against buffer D, it was
stored at80°C in small aliquots.
In vitro tests. 30S and 50S ribosomal subunits, 027-IF2Cp(A)mRNA,
EF-G, and E. coli cell extract were prepared as described previously (17,
18). In vitro mRNA translation driven by 027-IF2Cp(A) mRNA was car-
ried out as described previously (17). Native polyacrylamide (12%) gel
electrophoresis of EF-Tu preincubated with 1mMGTP in the presence of
increasing concentrations (0.1, 0.5, 1, 5, 10, 50, and 100M) of GE2270A
or NAI003 was performed in Tris-glycine buffer (pH 8.3) as described
previously (11).
Poly(U) hybrid translation system. Poly(U) translation was carried
out in 30 l of buffer E containing 3 mM phosphoenolpyruvate, 0.05
g/ml pyruvate kinase, 1 mMGTP, 0.15g/l poly(U), 10M [3H]Phe-
tRNA, and 0.2 M E. coli 30S, 50S, and EF-G. Twenty picomoles of puri-
fied EF-Tu (from E. coli, S. aureus, E. faecalis, S. pyogenes, or P. acnes) was
added to themixture after a 5-min incubation at room temperature in the
presence of increasing concentrations of GE2270A or NAI003. After 30
min at 37°C, the level of poly(U) translation was quantified from the
amount of acid-insoluble [3H]Phe-tRNA incorporated.
RESULTS
Synthesis of NAI003. The oxazolidine-linked L-Ser-L-Pro-NH2
side chain of GE2270A undergoes, on acid treatment, an N-O acyl
shift, forming a diketopiperazine ester that can be easily removed
by mild basic treatment (19, 20). The newly formed carboxylic
acid 2 can thus be effectively amidated, as for example with 4-ami-
no-N-benzylpiperidine, to afford NAI003 (Fig. 1).
Antibacterial spectrum of NAI003. The parent compound
GE2270A is highly active against Gram-positive bacteria but not
effective against Gram-negative species (10). Table 2 shows the
activity of GE2270A against Staphylococcus, Streptococcus, and En-
terococcus spp., with MICs in the ranges of0.015 to 0.25, 0.06 to
2, and 0.008 to 0.015g/ml, respectively. The acid derivative 2main-
tains substantially the same spectrum as GE2270A, although MICs
were32- to64-fold and4- to16-foldhigher against staphylococci and
streptococci, respectively (Table 2). Surprisingly, NAI003 had lost
potency against most of the tested strains: measurable MICs were
observed against Enterococcus spp., with MICs in the 0.5- to 16-
g/ml range, and against Mycobacterium smegmatis. Interestingly,
in the latter case, compounds 1, 2, and 3 were found to be equally
active,withMICsof 4 to 8g/ml (Table 2). It shouldbenoted that all
four Corynebacterium strains tested in this experiment were equally
insensitive to the three compounds, suggesting that this genusmaybe
insensitive to this class of thiopeptides (Table 2).
We then wondered whether, among the pathogenicActinobac-
teria, some species might have retained sufficient sensitivity to
NAI003. Preliminary experiments indicated that P. acnes was suf-
ficiently sensitive to this compound to warrant further investiga-
tion. The results of these evaluations are reported in Table 3,
where it can be seen that Propionibacterium spp., including P.
acnes, were highly sensitive to NAI003, with MIC values in the
range of 4 to 250 ng/ml. In contrast to most bacterial species in
Table 2, P. acnes appears to be equally sensitive to all of the three
thiopeptides tested in this study (Table 3). Among the tested P.
acnes isolates, one strain was highly resistant to clindamycin and
erythromycin, an increasingly frequent phenotype among P. acnes
isolates (21). As expected from their different targets, NAI003 and
GE2270 retained activity against this strain.
Killing effect onP. acnes.To our knowledge, a single study has
been performed to evaluate the effect of topical treatment on the
number of P. acnes cells on the forehead of healthy volunteers: a
reduction of approximately 1 log CFU was observed after 1 or 2
weeks of daily applications of 1% clindamycin (22, 23).
We thus wondered whether NAI003 had any effect in vitro on
the number of viable P. acnes cells in comparison with clindamy-
cin. To this end, we tested the effect of the two antibiotics when
added to exponentially growing cells. The results are illustrated in
Fig. 2A. Under the experimental conditions used, P. acnes reached
stationary phase (108 CFU/ml) after approximately 48 h, with an
apparent duplication time of 4 to 5 h. When these cultures were
exposed to clindamycin at 1, 10, or 100 the MIC, a slow
decline in viable counts was observed during the first 48 h, fol-
FIG 1 Synthetic route to NAI003. DPPA, diphenyl phosphorazidate.
Fabbretti et al.
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lowed by an apparent faster decline afterwards, resulting in viable
counts below the detection limit of the assay (around 20CFU/ml).
In contrast, the NAI003 killing rate was relatively constant with
time, leading after 6 days to a 2- and 3-log reduction in viable
counts at 10 and 100 theMIC. In the presence of 1 theMIC,
after an approximately 24-h lag, the strain was eventually able to
grow, albeit at a reduced rate (Fig. 2A).
A similar experiment was then performed with strain
ND063311, which is resistant to clindamycin (MIC, 64g/ml) but
equally sensitive to NAI003 (Table 2). While NAI003 could be
used again at 1, 10, and 100 the MIC, we could test clinda-
mycin only at 1 (i.e., 64 g/ml) and 4 (i.e., 256 g/ml) the
MIC. The results are shown in Fig. 2B. Neither clindamycin nor
NAI003 at 1 theMIChad a significant effect on the viable counts
of the strain but simply resulted in growth retardation and 1-log-
lower CFU per milliliter at stationary phase. At higher concentra-
tions, NAI003 was able to decrease the number of viable counts in
a dose-dependent manner, with again a 3-log reduction seen after
6 days. Interestingly, the behaviors of NAI003 and clindamycin at
intermediate concentrations (10 and 4 the MIC, respectively)
TABLE 2 MICs of GE2270A, compound 2, and NAI003 against selected Gram-positive bacteria
Species and strain
MIC (g/ml) of antibiotic:
GE2270A Compound 2 NAI003 Vancomycin
Staphylococcus aureus
ATCC 29213 0.015 0.5 128 1
ND041009 0.015 0.5 128 1
ND018107 0.015 1 128 0.25
ND018107 0.03 1 128 0.5
ND055710 0.03 1 128 0.5
ND055910 0.03 0.5 128 1
Staphylococcus epidermidis
ND006607 0.015 1 128 1
ND015007 0.125 2 128 2
ND020708 0.03 0.5 128 2
ND021208 0.03 2 128 2
ND024908 0.015 1 128 2
ND025708 0.03 1 128 2
ND026508 0.06 4 128 1
Staphylococcus capitis
ND004307 0.03 2 128 2
ND018807 0.25 8 128 2
Streptococcus agalactiae
ND050210 2 128 128 0.5
L310 2 32 128 0.5
Streptococcus pyogenes
L1303 0.5 2 128 0.5
L800 0.5 4 128 0.5
Streptococcus pneumoniae ATCC
49619
0.06 0.5 128 0.25
Enterococcus faecalis
VanS L559 0.008 NTa 0.5 0.5
VanA L560 0.008 NT 0.5 128
Enterococcus faecium
VanS L568 0.015 NT 16 2
VanA L569 0.015 NT 4 128
Mycobacterium smegmatismc2155 4 8 4 NT
Micrococcus luteus L108 0.015 1 128 0.125
Corynebacterium jeikeium
L2508 128 128 128 1
L2645 128 128 128 0.5
Corynebacterium sp.
L689 128 128 128 1
L691 128 128 128 0.5
a NT, not tested.
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were similar, with some decrease in viable counts up to 3 to 4 days,
followed by a tendency of viable counts to rebound (Fig. 2B).
In conclusion, these experiments indicate thatNAI003 at 100
theMIC (i.e., 1.5g/ml) can decrease the number of viable counts
to similar extents for both a clindamycin-sensitive (strain
ND062711) and a clindamycin-resistant (ND063111) strain. In
contrast, killing by clindamycin can occur against the sensitive
strain at lower MIC multiples and concentrations (i.e., 0.06 g/
ml) than those for NAI003. However, with the clindamycin-resis-
tant strain tested here, 256 g/ml clindamycin led to a lower re-
duction in viable counts than 1.5 g/ml NAI003.
NAI003 binds to and inhibits the function of EF-Tu from
Escherichia coli. To confirm that the molecular target of NAI003
is EF-Tu, the assay described by Anborgh and Parmeggiani was
initially used (12). This test takes advantage of the different mo-
bilities of free E. coli EF-Tu–GTP and of the EF-Tu–GTP–
GE2270A complex in native polyacrylamide gel electrophoresis
(12, 24).
The results shown in Fig. 3 indicate that NAI003 is indeed able
to alter the electrophoretic mobility of E. coli EF-Tu, thereby con-
firming that this elongation factor is also the target of this mole-
cule. It is also interesting that the difference in the electrophoretic
TABLE 3 MICs of GE2270A, compound 2, and NAI003 against P. acnes
Propionibacterium
acnes strain
MIC (g/ml) of antibiotic:
GE2270A Compound 2 NAI003 Erythromycin Clindamycin
ND062411 0.0018 0.03 0.015 0.03 0.06
ND062511 0.0018 0.06 0.015 0.06 0.125
ND062611 0.0018 0.06 0.06 0.06 0.06
ND062711 0.0018 0.06 0.015 0.03 0.06
ND062811 0.0018 0.06 0.015 0.03 0.06
ND062911 0.0018 0.03 0.03 0.06 0.03
ND063011 0.0018 0.03 0.007 0.06 0.5
ND063111 0.0018 0.06 0.015 0.06 0.06
ND063211 0.0018 0.03 0.015 0.06 0.06
ND063311 0.0009 0.03 0.015 128 64
L627 0.015 NTa 0.06 NT NT
ATCC 6919 0.008 NT 0.06 NT NT
ATCC 6922 0.03 NT 0.13 NT NT
ATCC 25746 0.03 NT 0.25 NT NT
L1559 0.008 NT 0.06 NT NT
L1560 0.015 NT 0.06 NT NT
L1561 0.015 NT 0.06 NT NT
L1562 0.008 NT 0.06 NT NT
L1563 0.008 NT 0.06 NT NT
L1564 0.015 NT 0.06 NT NT
L1565 0.015 NT 0.06 NT NT
a NT, not tested.
FIG 2 Killing kinetics of P. acnes. Effect of NAI003 (closed symbols, solid lines) and clindamycin (empty symbols, dashed lines) on the viability of P. acnes, using
the clindamycin-sensitive ND062711 (A) and clindamycin-resistant ND06311 (B) isolates. Compounds were added at 1MIC (triangles), 10MIC (circles),
or 100MIC (squares). In panel B, clindamycin was used at only 1 (open triangles) and 4 (open diamonds) the MIC. Growth controls are shown for both
panels by a thick dashed line.
Fabbretti et al.
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mobilities between free and antibiotic-bound EF-Tu is smaller for
NAI003 than forGE2270A (Fig. 3B). This finding suggests that the
interaction of the two antibiotics with EF-Tu induces different
conformational changes of the elongation factor. From the gel
shift experiments, it can be surmised that low concentrations (0.5
to 1 M) of GE2270A increase the mobility of more than 50% of
EF-Tu, while greater concentrations (approximately 10 M) of
the derivative are required to shift the same amount of protein. In
addition, from the gel shift experiments it can be observed that low
concentrations (0.5 to 1M) of GE2270A increase themobility of
EF-Tu by more than 50%, while greater concentrations (approx-
imately 10 M) of the derivative are required to shift the same
amount of protein.
GE2270A is known to inhibit in vitro protein synthesis in an E.
coli-based cell-free system. When the effect of NAI003 was com-
pared to that of GE2270A in an E. coli in vitro translation system
programmed with the 027-IF2Cp(A) mRNA (17), both antibiot-
ics proved to interfere with protein synthesis but to different ex-
tents: whereas GE2270A caused 50% inhibition of protein synthe-
sis at a 10 M concentration, a 10-fold-higher concentration of
NAI003 was necessary to achieve 25 to 30% inhibition only
(Fig. 3C).
From the results of the in vitro translation assays and from
those obtained with the gel shift experiments, it is possible to
deduce that both GE2270A and NAI003 form a stable interaction
with elongation factor EF-Tu that causes an altered electropho-
reticmobility of the protein in a native gel. However, the chemical
modification of GE2270A which gives rise to NAI003 reduces by
almost 1 order of magnitude the affinity of the latter antibiotic for
EF-Tu and also reduces its efficiency as a protein synthesis inhib-
itor in E. coli (Fig. 3C).
Effect ofNAI003 ondifferent EF-Tus.Tounderstandwhether
the difference in the antibacterial spectra of GE2270A andNAI003
might correlate with differences in affinities for the corresponding
EF-Tus, in vitro experiments were carried out with EF-Tu purified
fromvarious organisms, namely, theNAI003-insensitive S. aureus
and S. pyogenes, themoderately sensitive E. faecalis, and the highly
sensitive P. acnes. To do so, the tuf genes encoding the EF-Tus
from these organismswere amplified and cloned in the expression
vector pETM-11, following essentially the method described by
Zeng (16). This procedure and the presence of an N-terminal
oligohistidine tail afforded sufficient amounts of protein from the
four microorganisms after affinity chromatography. After purifi-
cation, the oligohistidine tail was removed by treatment with the
TEV protease and the affinities of these factors for NAI003 and for
GE2270A were compared by gel shift assays as described above.
As seen in Fig. 4, the different EF-Tus bind GE2270A with
approximately the same affinities, at least within the resolution
limits of the experimental technique used, but display appreciable
differences in their capacities to bindNAI003. Indeed, whereas the
FIG 3 Effects of GE2270A andNAI003 on the electrophoreticmobility of EF-Tu and on in vitro translation. (A)Migration on native polyacrylamide gel of E. coli
EF-Tu (preincubated with GTP) in the presence of increasing concentrations (from left to right, 0.1, 0.5, 1, 5, 10, 50, and 100 M) of GE2270A (lanes 2 to 8) or
NAI003 (lanes 9 to 15). (B) Electrophoretic mobility difference between EF-Tu–GTP alone (lane 1) and in the presence of 1 MGE2270A (lane 2) or of 10 M
NAI003 (lane 3). The two arrows indicate the different migrations of EF-Tu in complex with GE2270A or with NAI003. (C) Inhibition by GE2270A ()
or NAI003 () in a protein synthesis system based on an E. coli extract programmed with 027-IF2Cp(A) mRNA.
FIG 4 Effect of GE2270A and NAI003 on the electrophoretic mobilities of
different EF-Tus. Migration on native polyacrylamide gels of EF-Tu from E.
coli (A), S. aureus (B), P. acnes (C), and S. pyogenes (D) in the presence of
increasing concentrations (1, 4, 19, 50, and 100M, respectively) of GE2270A
(lanes 2 to 6) or of NAI003 (lanes 7 to 11).
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proteins from E. coli and P. acnes can clearly bind NAI003, as
judged from their different electrophoretic mobilities in the pres-
ence of increasing concentrations of the antibiotic, the same be-
havior was not observed for the factors from S. aureus and S.
pyogenes, whose mobilities are hardly affected by the presence of
NAI003.
The electrophoretic assay used in the experiments shown
above yields qualitative but not sufficiently quantitative data to
permit an estimation of the binding constants of the antibiotics
for the various types of EF-Tu. In fact, the altered mobility is
caused by the net electrical charge displayed on the protein surface
as a result of antibiotic-induced conformational change. Different
ligands can induce different changes on EF-Tu, and some of these
alterations may not trigger variations of the electrical charge. Fur-
thermore, the lack of a mobility shift does not constitute an abso-
lute proof of the lack of an interaction between the elongation
factors and the antibiotic. For these reasons, in vitro translation
tests were carried out to detect a possible inhibition of EF-Tu
function. Since EF-Tu is involved in the elongation stage of pro-
tein synthesis, these experiments were performed in a poly(U)-
dependent poly(Phe) synthesis test, a translational assay that does
not depend upon the complex initiation pathway of protein syn-
thesis (17). The tests were carried out using a hybrid system in
which ribosomes and EF-G purified from E. coli were incubated
with [3H]Phe-tRNA and a poly(U) template in the presence of an
appropriate energy-regenerating system and of the appropriate
EF-Tu protein.
When increasing amounts of EF-Tu originating from the se-
lected bacteria were added to the heterologous cell-free system,
the response was similar to that observed upon the addition of the
homologous E. coli EF-Tu. The addition of 10 pmol of E. coli
EF-Tu promoted the incorporation of90 pmol of [3H]Phe in a
hot-acid-insoluble product while the incorporation promoted by
the same amount of EF-Tu from P. acnes, S. aureus, and E. faecalis
was 40 pmol. The only exception was found with S. pyogenes
EF-Tu, whose efficiency was about 15% of that of E. coli (Fig. 5A).
These preliminary data indicate that the EF-Tus from the selected
bacteria are compatible with the E. coli components in the heter-
ologous translation system. In turn, these data indicate that this
type of test can be used to identify EF-Tu inhibitors, even in the
case of the less efficient S. pyogenes EF-Tu-dependent system, and
to compare the inhibitions by GE2270A and by NAI003 on the
different EF-Tus.
The graph presented in Fig. 5B shows that protein synthesis
was fully inhibited by GE2270A independently of the source of
EF-Tu, with a 50% inhibitory concentration (IC50) between 0.2
and 0.5M.With the exception of translation in the presence of S.
pyogenes EF-Tu, at 1 M GE2270A inhibition reached 100%
(Fig. 5B). The results obtained in the same test with NAI003 indi-
cate that at1 M this antibiotic caused25 to 30% inhibition
when translation depended upon E. coli or E. faecalis EF-Tu but
had no effect on the systems containing S. aureus or S. pyogenes
EF-Tus, which are only slightly inhibited at very high NAI003
concentrations (Fig. 5C). On the other hand, the translational
systems dependent on P. acnes EF-Tu proved to be the most sen-
sitive toNAI003 inhibition, translation being reduced by50%at
1 M NAI003 (Fig. 5C). These findings are overall consistent
with the conclusions drawn from the data presented in Fig. 4 and
allow for the conclusion that the replacement of the C-terminal
moiety in GE2270Awith the 4-amino-N-benzylpiperidinemoiety
present in NAI003 results in a weaker or different interaction of
the latter molecule with EF-Tu and a general reduction of its in-
hibitory activity. However, this same chemical modification re-
sulted in a molecule endowed with an increased selectivity in the
inhibition of EF-Tu from P. acnes.
Resistance to NAI003 is due to mutations in P. acnes EF-Tu.
The frequency of resistance to this class of thiopeptides was eval-
uated in parallel experiments with NAI003 and GE2270A. When
P. acnes was plated on medium containing 1 or 10 g/ml antibi-
otic, colonies appeared at frequencies of 6.3  1011 or 3.1 
1011, respectively, forGE2270A and at frequencies of 1.5 1010
and 9.4 1011, respectively, for NAI003.
Twelve independentNAI003r isolateswere evaluated and char-
acterized for the possible presence of mutations in the tuf gene,
encoding EF-Tu, as well as for their susceptibilities to GE2270A,
NAI003, and compound 2. With one exception, all resistant col-
onies harbored one mutation in the tuf gene for a total of 8 inde-
pendent changes at 6 different positions (Table 4). Some of the
observedmutations (G260R andG260C) occur at a residue (G257
in E. coli and Bacillus subtilis EF-Tu) previously reported to confer
FIG 5 Effects of GE2270A and NAI003 on in vitro protein synthesis. (A) Poly(U)-dependent incorporation of [3H]Phe in a hot-trichloroacetic acid-insoluble
product in the presence of increasing concentrations of different EF-Tus. The amounts of Phe incorporatedwith E. coli EF-Tu are indicated on the right ordinate,
while those obtainedwith EF-Tu fromP. acnes, S. aureus,E. faecalis, or S. pyogenes are indicated on the left ordinate. (B andC)Effects ofGE2270A (B) andNAI003
(C) on in vitro translation with different EF-Tus. Symbols for EF-Tu are as follows: black circles, E. coli; red diamonds, P. acnes; purple squares, E. faecalis; green
inverted triangles, S. aureus; turquoise triangles, S. pyogenes.
Fabbretti et al.
4566 aac.asm.org August 2015 Volume 59 Number 8Antimicrobial Agents and Chemotherapy
 o
n
 July 17, 2015 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
GE2270A resistance through the G257S substitution (11, 25, 26).
Interestingly, in the three-dimensional (3D) structure of the com-
plex betweenThermus thermophilus EF-Tu, GTP, andGE2270A, a
Gln residue (equivalent to Q99 in the P. acnes protein) makes
direct contact with the antibiotic. Consistently, three independent
P. acnes isolates carry the Q99H mutation. Finally, two indepen-
dent mutations (N276K and N276S) were observed at an Asn
residue (equivalent to N273 in the E. coli protein) that also makes
direct contact with the antibiotic (11). When transposed to the
crystal structure of T. thermophilus EF-Tu, the other observed
mutations (Table 4) map to domain I (H68Q and V81A) or II
(M263T), although they do not appear to be directly involved in
antibiotic binding.
In terms of resistance levels, some mutations (i.e., V81A,
G260C, and G260R) confer elevated protection to NAI003, while
mutant strains harboring the other mutations exhibit intermedi-
ate resistance (Table 4). Remarkably, although the different mu-
tations afforded an increased resistance to GE2270 or to com-
pound 2 with respect to the parental strain, none of them was
sufficient to confer resistance levels equivalent to those achieved
against NAI003 (Table 3). It should be noted, however, that we
sequenced the tuf gene only and the existence of additional muta-
tions elsewhere in the genome cannot be ruled out. Indeed, one
mutant (L1015R86) did not show any mutation in the tuf gene,
despite its high level of resistance to NAI003 (Table 4). Thus,
further studies will be necessary to understand the full range of
mutations conferring resistance to NAI003.
DISCUSSION
The results presented here demonstrate that NAI003 binds to the
EF-Tu from P. acnes with an affinity comparable to that of
GE2270A and that its binding alters the electrophoretic mobility
to the same extent as that observed with GE2270A. Furthermore,
the translation test performed demonstrates that NAI003 inhibits
in vitro P. acnes EF-Tu-dependent translation to a level similar to
that obtained with GE2270. That EF-Tu is the target of NAI003 in
vivo is confirmed by the observation that most spontaneous resis-
tant mutants of P. acnes carry mutations in the tuf gene, corre-
sponding to residues already established to confer resistance to or
to bind GE2270A (11).
GE2270A is a better inhibitor of P. acnes EF-Tu than its deriv-
ative NAI003. Consistently, GE2270AMICs tend to be lower than
those of NAI003. Nonetheless, we were surprised to observe that
mutations in EF-Tu that confer complete resistance to NAI003 in
vivo, some of which correspond to residues previously demon-
strated to be critical for GE2270A binding, afford only partial pro-
tection toGE2270A inP. acnes. Further studies will be necessary to
explain this observation.
We have demonstrated that the lack of sensitivity of many
Gram-positive bacteria to NAI003 is correlated with a lower inhi-
bition of their EF-Tus by this antibiotic. In this respect, the ob-
served extent of EF-Tu inhibition (Fig. 5C)well correlates with the
MIC values for the cognate microorganism (Table 1). It should be
noted that GE2270A is able to effectively inhibit all EF-Tus tested
so far, with natural resistance documented only in the producer
strain Planobispora rosea (25) and in the Corynebacterium species
tested here (Table 2). This is consistent with the fact that EF-Tu is
a highly conserved protein with limited variation among diver-
gent bacterial taxa. Despite these features, GE2270A has been con-
verted by a relatively simple chemical modification into a deriva-
tive with a dramatically reduced antibacterial spectrum. This has
resulted from the fortuitous occurrence of two factors: the highly
reduced susceptibility of EF-Tus from the three Firmicutes species
analyzed here and the lack of permeability of E. coli (and presum-
ably of other Gram-negative bacteria) to this class of thiopeptides,
which protect an otherwise partially sensitive EF-Tu. In light of
these results, it would be interesting to conduct further experi-
ments aimed at elucidating the 3D structure of the P. acnes EF-Tu
complexed with NAI003 and compare it to the EF-Tu–GE2270A
complex. This would provide insights into the nature of the dif-
ferent EF-Tu conformations induced by the two antibiotics and
enable predictive models of which bacterial strains may be sensi-
tive to NAI003 or to other GE2270A derivatives.
NAI003 was found to be equally active against 21 independent
P. acnes strains, including one highly resistant to clindamycin and
erythromycin (Table 3). Additional testing confirmed that this
GE2270A derivative retains activity against several independent
clindamycin- and erythromycin-resistant P. acnes clinical isolates
(D. Jabes, unpublished data). This observation is not surprising,
TABLE 4 Genotypes and phenotypes of P. acnes NAI003r mutants
Strain tufmutationa
EF-Tu MIC (g/ml) of antibiotic:
Substitutionb Domainc NAI003 GE2270A Compound 2
ATCC 6922 0.015 0.007 0.06
L1015R13 C207A H68Q I 8 0.015 0.5
L1015R51 T245C V81A I 32 0.06 1
L1015R6 G300T Q99H I 8 0.015 1
L1015R5 G300T Q99H I 2 0.007 0.5
L1015R7 G300T Q99H I 1 0.003 0.25
L1015R24 G781C G260R II 128 0.125 0.25
L1015R8 G781T G260C II 32 0.125 2
L1015R96 T791C M263T II 4 0.06 4
L1015R73 A830G N276S II 1 0.007 0.125
L1015R72 A830G N276S II 2 0.007 0.25
L1015R21 C831G N276K II 1 0.03 0.25
L1015R86 None None 128 0.25 4
a Nucleotide numbering is based on tuf sequence from P. acnes KPA171202 (15).
b Amino acid numbering is based on EF-Tu sequence from P. acnes KPA171202 (15).
c As defined by Parmeggiani et al. (11).
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since clindamycin and erythromycin resistance in P. acnesmostly
involves mutation in 23S RNA (27–29), a site unrelated to the
interaction of EF-Tu with the ribosome.
Antibacterial agents with an extremely narrow spectrum hold
the promise of curing infections with minimal disturbance of
commensal flora. Thismight be particularly true for topical appli-
cations, where a diverse and body-specific flora is expected to
contribute to skin health (30–32). The compound previously des-
ignated BIK 0376 has already completed a clinical study in healthy
volunteers as a topical application (32, 33). A clinical study will be
necessary to establish its efficacy.
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